Login to Your Account

Astrazeneca avoids share puncture on tralokinumab phase III asthma miss

By Marie Powers
News Editor

Wednesday, November 1, 2017

Bolstered hours earlier by FDA approval of the oral small-molecule Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib), Astrazeneca plc and its biologics research and development arm, Medimmune, quietly posted a miss for the phase III STRATOS 2 and TROPOS trials of tralokinumab, an anti-interleukin-13 (IL-13) immunoglobulin (IGE)-G4 monoclonal antibody, in severe, uncontrolled asthma.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription